Fool.com Headlines: Akorn Acquires U.S. Rights to Trio of Merck Eye Treatments

Fool.com Headlines Fool.com Headlines

Monitor all your apps! Deploy New Relic and get your Nerd Life t-shirt. Monitor any web or mobile app in less than 2 minutes. Don't let performance ruin your bottom line. From our sponsors

Akorn Acquires U.S. Rights to Trio of Merck Eye Treatments Nov 16th 2013, 01:01, by Eric Volkman, The Motley Fool The company will pay nearly $53 million in the deal.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions